Pricing, pharmacy rules and the business of running a clinic.
A clinic can source across multiple channels and still find that the available choices are not interchangeable. State-licensed pharmacies operating under section 503A and FDA-registered outsourcing facilities under section 503B face different conditions. The FDA's April GLP-1 update makes that distinction explicit, while its 503A bulks page describes another layer: not every nominated ingredient is on a final approved bulks list.
The landscape, then, is less a map of vendors than a matrix of questions. Who is the compounder? Which legal pathway applies? What is the ingredient's current status? Is the order tied to an identified patient and a documented need? The answer to one question cannot stand in for the others.
This analysis does not rank suppliers or imply that a given pharmacy can or cannot fill a given order today. Those are current-state facts to verify directly. The broader market lesson is that optionality comes from understanding the rules behind an order, not merely adding another source to an address book. For independent practices, the administrative process is part of the product experience, even when patients never see it.
Source status should be rechecked before publication. This is market reporting, not legal or clinical advice.